Samer Al Hadidi
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Samer Al Hadidi
Jun 26, 2024, 06:51 |
Insight
Samer Al Hadidi on academic moderation
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X:…
May 29, 2024, 09:46 |
Blog
Top 7 ASCO24 abstracts to watch for multiple myeloma by Samer Al Hadidi
Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, shared a post on X: "My top…
May 15, 2024, 14:51 |
Blog
Rahul Gosain: HemeSeries with Samer Al Hadidi for Relapsed/Refractory Multiple Myeloma
Rahul Gosain, Director of Regional Infusion Services at Wilmot Cancer Institute, shared on LinkedIn: "HemeSeries: with Samer…
Mar 17, 2024, 13:43 |
Insight
Samer Al Hadidi: How to counsel patients about Cilta Cel
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Dec 14, 2023, 15:41 |
Insight
Samer Al Hadidi: Will use of CAR-T earlier be better?
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Dec 1, 2023, 22:12 |
Blog
Samer Al Hadidi: Our study examined the prevalence and characteristics of subgroup analysis in oncology clinical trials
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on Twitter:…
Nov 14, 2023, 04:36 |
Blog
Manni Mohyuddin: We analyze use of terms that minimize toxicity in myeloma trials
Manni Mohyuddin, Assistant Professor, Huntsman Cancer Institute, University of Utah, shared a post on X/Twitter:…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube